全文获取类型
收费全文 | 1352篇 |
免费 | 146篇 |
国内免费 | 67篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 85篇 |
妇产科学 | 1篇 |
基础医学 | 87篇 |
口腔科学 | 43篇 |
临床医学 | 77篇 |
内科学 | 179篇 |
皮肤病学 | 59篇 |
神经病学 | 32篇 |
特种医学 | 12篇 |
外科学 | 341篇 |
综合类 | 149篇 |
现状与发展 | 1篇 |
预防医学 | 7篇 |
眼科学 | 72篇 |
药学 | 336篇 |
中国医学 | 56篇 |
肿瘤学 | 26篇 |
出版年
2024年 | 2篇 |
2023年 | 10篇 |
2022年 | 19篇 |
2021年 | 21篇 |
2020年 | 26篇 |
2019年 | 31篇 |
2018年 | 43篇 |
2017年 | 42篇 |
2016年 | 39篇 |
2015年 | 51篇 |
2014年 | 56篇 |
2013年 | 131篇 |
2012年 | 62篇 |
2011年 | 54篇 |
2010年 | 66篇 |
2009年 | 72篇 |
2008年 | 78篇 |
2007年 | 78篇 |
2006年 | 86篇 |
2005年 | 82篇 |
2004年 | 53篇 |
2003年 | 58篇 |
2002年 | 59篇 |
2001年 | 48篇 |
2000年 | 37篇 |
1999年 | 44篇 |
1998年 | 30篇 |
1997年 | 33篇 |
1996年 | 30篇 |
1995年 | 29篇 |
1994年 | 12篇 |
1993年 | 13篇 |
1992年 | 11篇 |
1991年 | 14篇 |
1990年 | 12篇 |
1989年 | 11篇 |
1988年 | 11篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 6篇 |
排序方式: 共有1565条查询结果,搜索用时 15 毫秒
1.
特异性荧光偏振免疫法监测521例肾移植后环孢素A全血浓度3275次 总被引:2,自引:0,他引:2
目的通过监测肾移植后病人环孢素A(CsA)全血浓度 ,提出CsA在三联免疫抑制用药方案中的理想治疗窗。方法用特异性荧光偏振免疫法测定CsA全血浓度 ,对521例病人监测3275次 ,按术后时间及临床表现分组比较。结果肾移植后<1 ,、1~3、3~6、6~12个月、1~2和>2年的CsA全血谷浓度的理想治疗窗应分别为250~450、200~400、150~300、100~250、100~200和100~180μg/L。结论CsA全血浓度在上述范围内 ,中毒反应和排异反应明显减少 相似文献
2.
Histamine-type 2 antagonists (H2-blockers) as represented by cimentidine have been shown to adversely affect renal allograft function, particularly when coadministered
with cyclosporine, currently a major immunosuppressant. To determine whether or not a newer and more powerful H2-blocker, famotidine, would produce similar adverse effects, we assessed seven cyclosporine-treated renal allograft recipients
with regard to changes in their renal function on or off the H2-blocker over a one-week period. Neither the administration nor withdrawal of famotidine (20–40 mg/day) resulted in any significant
changes in serum creatine, BUN, urine output or cyclosporine trough levels, suggesting that famotidine can be safely administered
as an H2-blocker to cyclosporine-treated renal allograft recipients. 相似文献
3.
The natural history of uveitis 总被引:8,自引:0,他引:8
Robert B. Nussenblatt 《International ophthalmology》1990,14(5-6):303-308
Summary Inflammatory diseases of the eye were known to the ancients, but only recently have the underlying mechanisms to this problem become better defined. During the middle portion of this century, most cases of uveitis thought to be caused by infectious agents, such as those responsible for syphilis and tuberculosis. Since then, it has become clear that endogenous mechanisms of immunomodulation play an important role in these disorders, which along with environmental and genetic factors make up an important triad. Animals studies have indicated the pivotal role of the T-cell in many of these disorders. The development of T-cell lines has helped to further delineate cell to cell interactions that occur during an ocular inflammatory event. The presence in the eye of uveitogenic antigens raises the strong possibility of autoimmune driven processes as well, similar to what is seen in the animal models. The better understanding of ocular inflammatory mechanisms has led to improved therapeutic strategies, including Sandimmune, and more recently Cyclosporine G, a related compound that may be less nephrotoxic. Newer therapeutic strategies will focus on even more novel modes of immunomodulation, probably without the use of medications. 相似文献
4.
罗格列酮对实验性慢性环孢素肾病的作用 总被引:5,自引:0,他引:5
目的 探讨罗格列酮(RSG)对慢性环孢素肾病(CCN)大鼠模型的肾保护作用。 方法 低盐饮食基础上建立CCN大鼠模型,其中1组模型鼠用RSG同时灌胃。分别在实验开始后第14天和第35天处死动物,检测血浆和肾组织血管紧张素Ⅱ(AngⅡ)、AngⅡ1型受体(AT1R)、转化生长因子β1(TGF-β1)、细胞外调节蛋白激酶(p-ERK)、α-SMA和纤连蛋白(FN)的表达。在体外用不同浓度的CsA和RSG孵育NRK细胞。RT-PCR检测肾皮质TGF-β1,Western印迹分析检测FN、AT1R、p-ERK水平。 结果 RSG可改善环孢素A导致的大鼠肌酐清除率的下降[(0.586±0.094)比(1.072±0.105)ml8226;min-18226;kg-1,P < 0.01]、血浆和肾组织AngⅡ水平增加(P < 0.01)、肾间质单核细胞浸润(P < 0.01)、肾间质纤维化(1.707±0.019 比 2.335±0.022,P < 0.01)、肾组织α-SMA表达增加(P < 0.01)、肾皮质TGF-β1 mRNA水平增加(P < 0.01)、NRK细胞FN、AT1R和p-ERK蛋白水平增加(P < 0.05)。 结论 RSG可能通过减轻炎细胞浸润、影响AngⅡ作用和下调TGF-β1等途径减轻CsA所致的肾组织损伤。 相似文献
5.
Large granular lymphocytic (LGL) leukaemia and chronic natural killer cell lymphocytosis (CNKL) are chronic indolent disorders often associated with neutropenia and constitutional symptoms. Severe anaemia occurs in about 20% of patients and is currently treated with corticosteroids followed by oral cyclophosphamide in non-responders. 30% of patients fail initial measures, and salvage therapy is inadequate. We describe three transfusion-dependent patients (two with T-LGL leukaemia, one with CNKL) refractory to corticosteroids, cyclophosphamide, and in one case fludarabine. Cyclosporine A (CSA) initiation resulted in prompt transfusion-independence and was well tolerated in all patients, making it an attractive alternative therapy for this disorder. 相似文献
6.
Amir Tejani Ping Leung Ho Lea Emmett Donald M Stablein 《American journal of transplantation》2002,2(2):142-147
Chronic rejection accounted for 32% of all graft losses in 7123 pediatric transplants. In a previous study acute, multiple acute and late acute rejections were risk factors for the development of chronic rejection. We postulated that the recent decrease in acute rejections would translate into a lower risk for chronic rejection among patients with recent transplants. We reviewed our data on patients transplanted from 1995 to 2000, and using multivariate analysis and a proportional hazards model developed risk factors for patients whose grafts had failed due to chronic rejection. A late initial rejection increased the risk of chronic rejection graft failure 3.6-fold (p < 0.001), while a second rejection resulted in further increase of 4.2-fold (p < 0.001). Recipients who received less than 5 mg/kg of cyclosporine at 30 days post-transplant had a relative risk (RR) of 1.9 (p = 0.02). Patients transplanted from 1995 to 2000 had a significantly lower risk (RR = 0.54, p < 0.001) of graft failure from chronic rejection than those who received their transplants earlier (1987-94). Since we were able to demonstrate that there is a decreased risk of chronic rejection graft failure in our study cohort, we would conclude that the goal of future transplants should be to minimize acute rejections. 相似文献
7.
Concomitant administration of cyclosporine and ketoconazole in idiopathic nephrotic syndrome. 总被引:1,自引:1,他引:0
Amr El-Husseini Fathy El-Basuony Ahmed Donia Ihab Mahmoud Nabil Hassan Nagy Sayed-Ahmad Mohamed Sobh 《Nephrology, dialysis, transplantation》2004,19(9):2266-2271
BACKGROUND: The deliberate use of ketoconazole to reduce the need for cyclosporine (CsA) is not new, but it is particularly relevant because of the high cost of CsA. Many studies have documented this benefit in renal and cardiac transplants, but this co-administration has not been reported in patients with nephrotic syndrome. METHODS: This retrospective study included 207 nephrotic patients who were steroid resistant, dependent or frequent relapsers and received CsA therapy. Among these patients 153 received daily ketoconazole therapy in a dose of 50 mg with concomitant decrease of one-third of the CsA dose while 54 patients received CsA alone. The majority of our cases were children (179 were below 18 years) and male to female ratio was 1.7:1. RESULTS: The great majority of the study population received the drugs for 1-2 years. Patients who received CsA and ketoconazole were comparable with those who received CsA alone regarding age, sex, duration of renal disease, renal pathology, severity of nephrotic syndrome, renal function, hepatic function and steroid response. Co-administration of ketoconazole significantly reduced mean doses of CsA by 37% after 1 month and 47% at 1 year with overall net cost savings of 37%. Hepatic functions remained within the normal range in both groups. Additionally, co-administration of ketoconazole significantly improved the response to CsA therapy, successful steroid withdrawal and decreased the frequency of renal impairment. CONCLUSIONS: Co-administration of keto with CsA in idiopathic nephrotic patients significantly reduces CsA costs and may improve its response. 相似文献
8.
9.
Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients 总被引:2,自引:0,他引:2
T. Heller T. van Gelder K. Budde J. W. de Fijter D. Kuypers W. Arns J. Schmidt L. Rostaing S. H. Powis K. Claesson I. A. M. MacPhee E. Pohanka J. Engelmayer G. Brandhorst M. Oellerich V. W. Armstrong 《American journal of transplantation》2007,7(7):1822-1831
The aim of this study was to determine whether plasma concentrations of the acyl (AcMPAG) and phenolic (MPAG) glucuronide metabolites of mycophenolic acid (MPA) were related to diarrhoea in renal transplant patients on mycophenolate mofetil (MMF) with cyclosporine (CsA) or tacrolimus (TCL). Blood samples (0, 30, 120 min) were taken at days 3, 10, week 4, months 3, 6 and 12 for determination of MPA, MPAG and AcMPAG. MPA-AUC was estimated using validated algorithms. Two hour AUCs were calculated for MPAG and AcMPAG. Immunosuppressive therapy consisted of CsA/MMF (n= 110) and of TCL/MMF (n= 180). In 70/290 (24%) patients 86 episodes of diarrhoea were recorded during 12 months. Significantly more patients on TCL (31.1%) suffered from diarrhea compared to CsA (12.7%). MMF dose, MPA-AUC and the 2 h AUCs of MPAG and AcMPAG did not differ between patients with and without diarrhoea. Plasma AcMPAG and MPAG concentrations were substantially higher in patients on CsA compared with TCL, while MPA-AUC was lower in the former group. These data support the concept that CsA inhibits the biliary excretion of MPAG and AcMPAG, thereby potentially reducing the risk of intestinal injury through enterohepatic recycling of MPA and its metabolites. 相似文献
10.
B. J. Nankivell M. D. Wavamunno R. J. Borrows M. Vitalone C. L-S Fung R. D. M. Allen J. R. Chapman P. J. O'Connell 《American journal of transplantation》2007,7(2):366-376
Mycophenolate mofetil (MMF) reduces acute rejection in controlled trials of kidney transplantation and is associated with better registry graft survival. Recent experimental studies have demonstrated additional antifibrotic properties of MMF, however, human histological data are lacking. We evaluated sequential prospective protocol kidney biopsies from two historical cohorts treated with cyclosporine (CSA)-based triple therapy including prednisolone and either MMF (n = 25) or azathioprine (AZA, n = 25). Biopsies (n = 360) were taken from euglycemic kidney-pancreas transplant recipients. Histology was independently assessed by the Banff schema and electron microscopic morphometry. MMF reduced acute rejection and OKT3 use (p < 0.05) compared with AZA. MMF therapy was associated with limited chronic interstitial fibrosis, striped fibrosis and periglomerular fibrosis (p < 0.05-0.001), mesangial matrix accumulation (p < 0.01), chronic glomerulopathy scores (p < 0.05) and glomerulosclerosis (p < 0.05). MMF was associated with delayed expression of CSA nephrotoxicity, reduced arteriolar hyalinosis, striped fibrosis and tubular microcalcification (p < 0.05-0.001). The beneficial effects of MMF remained in recipients without acute rejection. Retrospective analysis shows that MMF therapy was associated with substantially reduced fibrosis in the glomerular, microvascular and interstitial compartments, and a delayed expression of CSA nephrotoxicity. These outcomes may be due to a limitation of immune-mediated injury and suggest a direct effect of reduced fibrogenesis. 相似文献